세계의 사이토카인 시장 보고서 : 사이토카인 유형, 치료 용도, 최종 사용자, 지역별(2024-2032년)

The global cytokine market size reached US$ 89.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 163.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.76% during 2024-2032.

A cytokine refers to a group of proteins, peptides, or glycoproteins released by specific cells to control the growth and activity of the immune system and blood cells. It can regulate immunity, inflammation, and hematopoiesis on account of its high-affinity picomolar concentrations. It is usually injected under the skin or into muscles or veins to help prevent or manage chemotherapy side effects and treat cancer. It also boosts anti-cancer activities by sending signals that make abnormal cells die and normal cells live longer. Presently, it is gaining widespread adoption in cell and gene therapy for the expansion and differentiation of various cell types, ex vivo cultures, and other therapeutic approaches.

Cytokine Market Trends:

The coronavirus disease (COVID-19) is transmitted via droplets that can induce the excessive production of proinflammatory cytokines and lead to acute respiratory distress syndrome (ARDS) aggravation and tissue damage. As tissue damage can result in multi-organ failure and death, there is a rise in the demand for solutions that target cytokines to manage patients, improve survival rates, and reduce mortality. Apart from this, the increasing prevalence of cancer, in confluence with the escalating demand for minimally invasive surgeries (MIS) that provide less post-operative pain and complications and faster recovery time, is contributing to the market growth. Moreover, as cytokines act as diagnostic, prognostic, and therapeutic agents and biomarkers for health and diseases, they are gaining traction in diverse functions, including immune cell differentiation, inflammation, angiogenesis, tumorigenesis, neurobiology, and viral pathogenesis. Besides this, the rising cases of atopic dermatitis (AD), a recurrent, chronic, and inflammatory skin disease that processes with severe itchiness, is driving the demand for new cytokines in the pathogenesis of AD and developing improved therapeutic targets.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cytokine market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on cytokine type, therapeutic application and end user.

Breakup by Cytokine Type:

Tumor Necrosis Factor-TNF

Interleukins-Il

Interferons-IFN

Epidermal Growth Factor-EGF

Others

Breakup by Therapeutic Application:

Cancer

Asthma and Airway Inflammation

Arthritis

Others

Breakup by End User:

Pharmaceutical and Biotechnology Companies

Contract Research Organizations

Academic and Research Institutes

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Abcam plc, Amgen Inc., Applied Biological Materials Inc. (abm), Bio-Techne Corporation, F. Hoffmann-La Roche AG, GenScript Biotech Corporation, Randox Laboratories Ltd., Thermo Fisher Scientific Inc. and UCB S.A.

Key Questions Answered in This Report:

• How has the global cytokine market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global cytokine market?
• What are the key regional markets?
• What is the breakup of the market based on the cytokine type?
• What is the breakup of the market based on the therapeutic application?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global cytokine market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cytokine Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Cytokine Type

• 6.1 Tumor Necrosis Factor-TNF
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Interleukins-Il
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Interferons-IFN
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Epidermal Growth Factor-EGF
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Therapeutic Application

• 7.1 Cancer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Asthma and Airway Inflammation
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Arthritis
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by End User

• 8.1 Pharmaceutical and Biotechnology Companies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Contract Research Organizations
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Academic and Research Institutes
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AbbVie Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Abcam plc
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Amgen Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 Applied Biological Materials Inc. (abm)
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Bio-Techne Corporation
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 F. Hoffmann-La Roche AG
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 GenScript Biotech Corporation
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Randox Laboratories Ltd.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Thermo Fisher Scientific Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 UCB S.A.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials